{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030372","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.046064+00:00","generated_at":"2026-05-31T12:13:05.578055+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"InspireMD Q2 2024 revenue up 5.4% to $1.74M; net loss widens; positive CGuard trial data","bullets":["Q2 2024 revenue $1.74M (+5.4% YoY); gross margin fell to 19.0% from 29.8% on higher costs.","Net loss $7.9M ($0.22/share) vs $5.1M ($0.24) YoY; operating expenses up 48% to $8.6M.","CGuard stent sales 2,969 units; one-year C-GUARDIANS trial primary endpoint rate 1.95% (lowest ever).","Raised $17.9M gross from full exercise of Series H warrants; cash & equivalents $47.2M at June 30.","Intends to submit PMA application to FDA this quarter; plans CGUARDIANS II TCAR trial in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030372","json":"https://secwatch.observer/filing/0001493152-24-030372.json","markdown":"https://secwatch.observer/filing/0001493152-24-030372.md","text":"https://secwatch.observer/filing/0001493152-24-030372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224030372/0001493152-24-030372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224030372/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:13:05.578055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}